Retatrutide + Tirzepatide
Also known as: Triple + Dual Combo, Reta-Tirz, Maximum Incretin Stack
A combination of triple and dual agonists for aggressive weight management.
Overview
This combination pairs retatrutide (GLP-1/GIP/glucagon) with tirzepatide (GLP-1/GIP). While there is significant receptor overlap, some users combine these for aggressive weight loss protocols. This is not a recommended or validated approach.
Mechanism of Action
Both activate GLP-1 and GIP receptors (overlapping). Retatrutide adds glucagon receptor activation. Combination may provide redundant GLP-1/GIP activity with additional glucagon effects.
Pharmacokinetics
Both are weekly injectables. Overlapping mechanisms mean effects may not be additive.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
NOT RECOMMENDED
Variable
Weekly
N/A
This combination is not recommended due to overlapping mechanisms
Research Areas
Key Research Findings
- 1NOT a recommended combination
- 2Significant receptor overlap
- 3No clinical validation
- 4Risk of severe side effects
Side Effects & Contraindications
Reported Side Effects
- Severe nausea
- Vomiting
- Diarrhea
- Dehydration risk
- Malnutrition risk
Contraindications
- Most users should avoid this combination
- All GLP-1 contraindications apply
Safety Considerations
NOT RECOMMENDED - overlapping mechanisms may increase side effects without proportional benefit. No safety data for combination. Extreme GI side effects likely.
Storage Requirements
Refrigerate 2-8°C
Scientific References
- 1